These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 12082292)

  • 21. CD24 is highly useful in differentiating high-grade serous carcinoma from benign and malignant mesothelial cells.
    Davidson B
    Hum Pathol; 2016 Dec; 58():123-127. PubMed ID: 27589896
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic value of a second generation CA 15-3 antibody to detect adenocarcinoma in body cavity effusions.
    Zimmerman RL; Fogt F; Goonewardene S
    Cancer; 2000 Aug; 90(4):230-4. PubMed ID: 10966563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Death domain-associated protein (DAXX) expression is associated with poor survival in metastatic high-grade serous carcinoma.
    Davidson B; McFadden E; Holth A; Brunetti M; Flørenes VA
    Virchows Arch; 2020 Dec; 477(6):857-864. PubMed ID: 32533344
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Significance of flower pot cells in effusion cytology.
    Bharani V; Singh P; Gupta N; Srinivasan R
    Diagn Cytopathol; 2017 Oct; 45(10):925-927. PubMed ID: 28560851
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumor microenvironment: what can effusions teach us?
    Kassis J; Klominek J; Kohn EC
    Diagn Cytopathol; 2005 Nov; 33(5):316-9. PubMed ID: 16240401
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Detection of a soluble antigen defined by monoclonal antibody 83D4 in serous effusions associated with breast carcinoma.
    Osinaga E; Pancino G; Beuzelin M; Babino A; Rodriguez D; Robello C; Tiscornia A; Phillips E; Bourguignat A; Roseto A
    Cancer; 1992 Apr; 69(7):1745-9. PubMed ID: 1551059
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heat shock protein 90 is a putative therapeutic target in patients with recurrent advanced-stage ovarian carcinoma with serous effusions.
    Elstrand MB; Stavnes HT; Tropé CG; Davidson B
    Hum Pathol; 2012 Apr; 43(4):529-35. PubMed ID: 21864883
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Osteopontin expression in ovarian carcinoma effusions is related to improved clinical outcome.
    Davidson B; Holth A; Moripen L; Trope' CG; Shih IeM
    Hum Pathol; 2011 Jul; 42(7):991-7. PubMed ID: 21315424
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kallikrein 4 expression is up-regulated in epithelial ovarian carcinoma cells in effusions.
    Davidson B; Xi Z; Klokk TI; Tropé CG; Dørum A; Scheistrøen M; Saatcioglu F
    Am J Clin Pathol; 2005 Mar; 123(3):360-8. PubMed ID: 15716231
    [TBL] [Abstract][Full Text] [Related]  

  • 30. SCARA3 mRNA is overexpressed in ovarian carcinoma compared with breast carcinoma effusions.
    Bock AJ; Nymoen DA; Brenne K; Kærn J; Davidson B
    Hum Pathol; 2012 May; 43(5):669-74. PubMed ID: 21855113
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Without prior stimulation, tumor-associated lymphocytes from malignant effusions lyse autologous tumor cells in the presence of bispecific antibody HEA125xOKT3.
    Strauss G; Gückel B; Wallwiener D; Moldenhauer G
    Clin Cancer Res; 1999 Jan; 5(1):171-80. PubMed ID: 9918216
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Diagnostic utility of GLUT-1 expression in the cytologic evaluation of serous fluids.
    Afify A; Zhou H; Howell L; Paulino AF
    Acta Cytol; 2005; 49(6):621-6. PubMed ID: 16450901
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HMGA2 protein expression in ovarian serous carcinoma effusions, primary tumors, and solid metastases.
    Hetland TE; Holth A; Kærn J; Flørenes VA; Tropé CG; Davidson B
    Virchows Arch; 2012 May; 460(5):505-13. PubMed ID: 22476403
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serous effusions in malignant lymphomas: a review.
    Das DK
    Diagn Cytopathol; 2006 May; 34(5):335-47. PubMed ID: 16604559
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Wee1 is a novel independent prognostic marker of poor survival in post-chemotherapy ovarian carcinoma effusions.
    Slipicevic A; Holth A; Hellesylt E; Tropé CG; Davidson B; Flørenes VA
    Gynecol Oncol; 2014 Oct; 135(1):118-24. PubMed ID: 25093290
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunocytochemical differentiation of reactive mesothelial cells and adenocarcinoma cells in serous effusions with the use of carcinoembryonic antigen and fibronectin.
    Athanassiadou P; Athanassiades P; Lazaris D; Kyrkou K; Petrakakou E; Aravantinos D
    Acta Cytol; 1994; 38(5):718-22. PubMed ID: 8091904
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Endoglin (CD105) expression in ovarian serous carcinoma effusions is related to chemotherapy status.
    Bock AJ; Tuft Stavnes H; Kærn J; Berner A; Staff AC; Davidson B
    Tumour Biol; 2011 Jun; 32(3):589-96. PubMed ID: 21350924
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Wilms tumor 1/cytokeratin dual-color immunostaining reveals distinctive staining patterns in metastatic melanoma, metastatic carcinoma, and mesothelial cells in pleural fluids: an effective first-line test for the workup of malignant effusions.
    Conner JR; Cibas ES; Hornick JL; Qian X
    Cancer Cytopathol; 2014 Aug; 122(8):586-95. PubMed ID: 25044880
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HLA-G expression in effusions is a possible marker of tumor susceptibility to chemotherapy in ovarian carcinoma.
    Davidson B; Elstrand MB; McMaster MT; Berner A; Kurman RJ; Risberg B; Trope CG; Shih IeM
    Gynecol Oncol; 2005 Jan; 96(1):42-7. PubMed ID: 15589578
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calretinin. A selective marker of normal and neoplastic mesothelial cells in serous effusions.
    Barberis MC; Faleri M; Veronese S; Casadio C; Viale G
    Acta Cytol; 1997; 41(6):1757-61. PubMed ID: 9390137
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.